Duration of Action: Temazepam, Lorazepam, and Diazepam
Temazepam has a short-to-intermediate duration of action (elimination half-life 8.8 hours), lorazepam has an intermediate duration (elimination half-life 15.7 hours with clinical effects lasting up to 72 hours), and diazepam has a prolonged duration of action (elimination half-life 51.2 hours) due to active metabolites that accumulate, particularly in patients with renal dysfunction.
Temazepam
Pharmacokinetic Profile:
- Elimination half-life: 3.5-18.4 hours (mean 8.8 hours) 1
- Duration classification: Short-to-intermediate-acting 2
- Time to peak plasma levels: 1.2-1.6 hours after dosing 1
- Active metabolites: None of clinical significance 1, 3
The FDA label specifies that temazepam undergoes complete metabolism through conjugation, with 80-90% appearing in urine as the O-conjugate metabolite 1. This lack of active metabolites distinguishes temazepam from longer-acting benzodiazepines and contributes to its more predictable duration of action 3, 4.
Clinical implications: Temazepam is classified as short-to-intermediate-acting in sleep medicine guidelines, making it appropriate for both sleep onset and maintenance insomnia 2. The relatively short half-life means minimal residual sedation the next morning at standard doses (7.5-30 mg), though some morning impairment can occur at doses ≥30 mg 3, 5.
Lorazepam
Pharmacokinetic Profile:
- Elimination half-life: 15.7 hours 6
- Clinical duration of action: Up to 72 hours after single IV dose 7, 8
- Volume of distribution (unbound): 12 L/kg 6
- Active metabolites: None 9
Critical distinction: While lorazepam's elimination half-life is shorter than diazepam's, its clinical duration of action is paradoxically much longer 7, 8, 6. This occurs because lorazepam has a much smaller volume of distribution of unbound drug compared to diazepam (12 L/kg vs 133 L/kg), meaning it remains at the receptor site longer despite faster elimination 6.
The 2013 ICU guidelines note that lorazepam's elimination half-life and duration of clinical effect are increased in renal failure 10. Additionally, emergence from short-term sedation (1-2 days) may be longer with lorazepam than midazolam due to greater potency and slower clearance 10.
Clinical implications: Lorazepam is not specifically FDA-approved for insomnia but may be considered when duration of action is appropriate for the patient's presentation 2. In status epilepticus, lorazepam's longer duration of action (several hours after single IV dose) makes it preferable to diazepam for initial management 8.
Diazepam
Pharmacokinetic Profile:
- Elimination half-life: 51.2 hours 6
- Clinical duration of action: <2 hours after single IV dose (for acute seizures) 7
- Duration classification: Long-acting with prolonged effects due to active metabolites 10
- Volume of distribution (unbound): 133 L/kg 6
The paradox of diazepam: Despite having the longest elimination half-life of these three benzodiazepines, diazepam has the shortest initial duration of action (<2 hours) after a single dose 7, 8. This occurs because diazepam is highly lipid-soluble and rapidly redistributes from the brain into peripheral tissues 6, 9.
However, with repeated dosing or prolonged administration, diazepam has a prolonged duration of action due to:
- Saturation of peripheral tissues 10
- Active metabolites that accumulate, especially in renal dysfunction 10
The 2013 ICU guidelines explicitly state that diazepam has a "prolonged duration of action due to saturation of peripheral tissues and active metabolites that can accumulate in patients with renal insufficiency" 10.
Clinical implications: The 2008 insomnia guidelines note that flurazepam (similar long-acting profile) is "rarely prescribed because of its extended half-life" 2. Diazepam carries risk of residual daytime drowsiness and accumulation with repeated use 2.
Comparative Summary
For single-dose administration:
- Diazepam: Shortest clinical effect (<2 hours) despite longest half-life
- Temazepam: Intermediate effect (8-12 hours)
- Lorazepam: Longest clinical effect (up to 72 hours)
For repeated/prolonged administration:
- Temazepam: Predictable, no accumulation of active metabolites
- Lorazepam: Moderate accumulation, especially with renal failure
- Diazepam: Significant accumulation with prolonged duration due to active metabolites
Common pitfall: Clinicians often assume that elimination half-life directly correlates with duration of action. This is incorrect for benzodiazepines—the volume of distribution of unbound drug and presence of active metabolites are equally or more important 7, 8, 6.